Aplastic anaemia: Management

Blood Reviews

Volumn 14, Issue 3, 2000, Pages 157-171

  Killick, S B ^a   Marsh, J C W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; HEMOSIDERIN; HLA ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; AVASCULAR NECROSIS; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; NEUTROPENIA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0033806641     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0133     Document Type: Review

References (116)

1. Incidence of aplastic anemia: The relevance of diagnostic criteria
2. Haemopoietic cell destruction by immune mechanisms in acquired aplastic anemia
3. Stem cell defect in aplastic anaemia
4. Severe aplastic anaemia: A prospective study of the effect of early marrow transplantation on acute mortality
5. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA working party
6. Treatment of acquired aplastic anaemia: Bone marrow transplantation compared with immunosuppressive therapy. The European Group for Blood and Marrow Transplant experience
7. When should the clinician suspect a drug-induced blood dyscrasia, and how should he proceed?
8. Aplastic anaemia
9. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins
10. Development of the glycosylphosphatitylinositol anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia
11. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: Search for a pathogenetic link
12. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party
13. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT)
14. Morphology in patients with severe aplastic anemia treated with antilyrophocyte globulin
15. Epidemiology of aplastic anaemia
16. Incidence of aplastic anemia in Bangkok. The Aplastic Anemia Study Group
17. An association of aplastic anaemia in Thailand with low socioeconomic status. Aplastic Anemia Study Group
18. Hepatitis-associated aplastic anemia
19. Aplastic anaemia and remoxipride
20. Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy')
21. Is it time to stop using chloramphenicol on the eye? Prospective study of aplastic anaemia should give definitive answer
22. Aplastic anemia and pesticides. An etiologic association?
23. Hematopoietic malignancies and related disorders among benzene-exposed workers in China
24. Pregnancy associated aplastic anaemia: A report of five cases and review of current management
25. Haematological and immunological abnormalities in eating disorders
26. Aplastic anaemia in systemic lupus erythematosus: A cellular immune mechanism?
27. Transfusion-associated graft-versus-host disease
28. The aplastic presentation of childhood leukaemia - A feature of common ALL
29. Morphology in patients with severe aplastic anaemia treated with antilymphocyte globulin
30. Myelodysplastic syndrome and aplastic anaemia: Distinct entities or diseases with a common pathophysiology
31. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anaemia
32. Cytogenetic abnormalities in aplastic anaemia
33. Abnormal cytogenetic clones in patients with aplastic anaemia: Response to immunosuppressive therapy
34. Cytogenetic abnormalities in patients with aplastic anaemia
35. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia
36. Long-term platelet support of patients with aplastic anemia. Effect of splenectomy and steroid therapy
37. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: A multivariate analysis of data from 264 cases
38. Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens
39. Haematopoietic growth factors in the pathogenesis and for the treatment of aplastic anaemia
40. Haemopoietic growth factors in aplastic anaemia: A cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia
41. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anaemia
42. Long term follow up of allogeneic marrow transplants in patients with aplastic anaemia conditioned with cyclophosphamide with antithymocyte globulin
43. Stable mixed haemopoietic chimerism in DLA identical littermate dogs given sublethal total body irradiation before and after pharmacological immunosuppression after marrow transplantation
44. Marrow transplanted for treatment of aplastic anaemia. An analysis of factors associated with graft rejection
45. HLA identical sibling bone marrow transplantation to treat severe aplastic anaemia
46. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anaemia patients
47. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft versus host disease
48. Chronic graft versus host disease after allogeneic peripheral blood progenitor cell or bone marrow transplant from matched related donors: A case control study
49. Bone marrow transplantation for severe aplastic anemia: Has outcome improved?
50. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group
51. Malignancies after haemopoietic stem cell transplantation: Many questions, some answers
52. Long term outcome after marrow transplantation for severe aplastic anaemia
53. Pregnancies following high dose cyclophosphamide with or without high dose busulphan or total body irradiation and bone marrow transplantation
54. Bone marrow transplant experience for children with aplastic anaemia
55. Bone marrow transplantation in 107 patients with severe aplastic anaemia using cyclophosphamide and thoracoabdominal irradiation for conditioning: Long term follow up
56. Malignancies after marrow transplantation for aplastic anaemia and Fanconi anaemia: A joint Seattle and Paris analysis of results in 700 patients
57. Bone marrow transplantation from donors other than HLA identical siblings: A report of the EBMT Working Party
58. Bone marrow transplantation for severe aplastic anaemia from genotypically HLA non identical relatives
59. Alternative donor bone marrow transplantation for severe acquired aplastic anaemia
60. Probability of finding HLA matched unrelated donors
61. Histocompatible unrelated volunteer donors compared with HLA non-identical family donors in marrow transplantation for aplastic anaemia and leukaemia
62. Changing trends in marrow transplantation for aplastic anaemia
63. Results of transplantating bone marrow from genetically identical twins into patients with aplastic anaemia
64. Fate of patients undergoing unrelated donor searches in the UK
65. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
66. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults
67. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: Confirmation of UR-BMT as a standard therapy for patients with leukaemia and aplastic anaemia
68. Guidelines for treating aplastic anaemia
69. Marrow transplantation from unrelated donors for patients with aplastic anaemia (AA) - Optimisation of a conditioning regimen
70. Marrow transplantation from unrelated donors for patients with severe aplastic anaemia who have failed immunosuppressive therapy
71. Bone marrow graft in man after conditioning by antilymphocytic serum
72. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions
73. A comprehensive definition of the major antibody specificites in polyclonal rabbit antithymocyte globulin
74. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins
75. Lymphokine abnormalities in aplastic anaemia: Implications for the mechanism of action of antithymocyte globulin
76. In vitro production of granulocyte-macrophage colony stimulating factor in aplastic anaemia: Possible mechanisms of action of antithymocyte globulin
77. Effect of antilymphocyte globulin (ALG) on bone marrow T/non-T cells for aplastic anaemia patients and normal controls
78. Induction of Fas (Apo-1, CD95) - Mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins
79. Differenetiation of normal marrow and HL60 cells induced by antithymocyte globulin
80. The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells
81. Effect of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia
82. Therapy of aplastic anaemia: Is a consensus possible?
83. Classification and aetiology of the aplastic anaemias
84. Aplastic anaemia: An analysis of 174 patients
85. Transient pancytopenia. A report from the International Agranulocytosis and Aplastic Study
86. What is the definition of cure of aplastic anaemia?
87. Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial
88. Severe aplastic anaemia: Correlation of in vitro tests with clinical response to immunosuppression in 20 patients
89. Results of immunosuppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplantation (EGBMT)
90. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high dose methyl prednisolone
91. Results of immunosuppression in aplastic anaemia
92. Do abdrogens enhance the response to antithymocyte globulin in patients with aplastic anaemia? A prospective randomised trial
93. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party
94. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia
95. Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure
96. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group
97. Immunosuppressive therapy of aplastic anaemia with antithymocyte globulin and cyclosporine
98. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia
99. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia
100. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party
101. Results of a randomised study of glycosylated rHuG-CSF Lenograstim in severe aplastic anaemia
102. Myelodysplastic syndrome and acute myeloid leukaemia as late complications in children with acquired aplastic anaemia
103. Long term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 in adults
104. Treatment of children with acquired aplastic anaemia
105. Effectiveness of immunosuppressive therapy in older patients with aplastic anaemia
106. The haemnatopoietic defect in aplastic anaemia assessed by long term marrow culture
107. The assessment of the haemopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anaemia
108. Relapse of aplastic anaemia after immunosuppressive treatment: A report from the European Bone Marrow Transplantation Group SAA Working Party
109. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia
110. Is aplastic anaemia a pre-leukaemic disorder?
111. Late clonal diseases of treated aplastic anaemia
112. Campath-1G in vivo confers a low incidence of graft versus host disease associated with a high incidence of mixed chimerism after bone marrow transplantation for severe aplastic anaemia using HLA identical sibling donors
113. Recovery from aplastic anaemia after treatment with cyclophosphamide
114. Complete remission in severe aplastic anaemia after high dose cyclophosphamide without bone marrow transplantation